Health Care·Biotechnology·$2.8B
Kodiak Sciences Inc is a biotechnology company focused on developing therapies for eye diseases. As part of the health care sector, its innovations could significantly impact the treatment landscape for vision-related conditions, which is a growing area of medical need.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely watch.
Revenue Growth
Although revenue estimates are not available, any signs of revenue growth would indicate successful product development and market acceptance.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
-0.18%
Avg Stock Reaction
-0.23%
In Q4 2025, Kodiak reported an EPS of -$1.04, slightly missing expectations. The stock reacted positively, gaining 13.25% the following day.
Management Promises & Guidance
Investors are cautiously optimistic about Kodiak's upcoming earnings, especially given the company's focus on innovative treatments in a vital health sector.
Bull Case
If Kodiak can demonstrate progress in its clinical trials or show better-than-expected EPS, it could lead to increased investor confidence and a significant stock price jump.
Bear Case
On the other hand, if the company reports wider losses or delays in its clinical trials, it could lead to a sharp decline in stock price as investors reassess the company's future prospects.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely watch.
Revenue Growth
N/AAlthough revenue estimates are not available, any signs of revenue growth would indicate successful product development and market acceptance.
Clinical Trial Updates
N/AUpdates on ongoing clinical trials are crucial for assessing the potential success of their therapies and future revenue streams.
The print will turn on these two things.
Q1
What are the latest updates on clinical trials for Kodiak's lead therapies?
Progress or setbacks in clinical trials can significantly influence investor sentiment and the stock price.
Q2
How does Kodiak plan to manage its cash burn in the upcoming quarters?
Understanding the company's financial strategy is crucial, especially if losses continue, as it can affect funding for future projects.
Why consensus could be wrong
The Street may be underestimating the potential for Kodiak's therapies to gain traction in the market, especially if clinical trial results are favorable.
Supporting Evidence
Options pricing suggests a significant move, indicating traders expect volatility that could favor a positive outcome.
Historical performance shows that the stock has reacted positively to news despite recent misses, suggesting underlying strength.
The biotechnology sector is seeing increased investment, which could benefit Kodiak if it shows progress.
Key Risk
If clinical trial results exceed expectations, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is closely watching Kodiak's ability to balance innovation with financial sustainability, which will be critical for its future.
Bull Confirmed If
Positive updates on clinical trials that suggest a path to regulatory approval.
Bear Confirmed If
Wider-than-expected losses or delays in clinical trial timelines.
Implied Move
±50.3%
Historical Avg
±4.3%
The options market is pricing in a significant move, indicating that traders expect high volatility around the earnings report.
Options are pricing ±50.3% while KOD has averaged ±4.3% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
n=30Fade rate: 11 of 27 (41%)
This setup has occurred 30 times across Health Care in the last 2 years. 11 of 27 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 6.3%, with a raw directional average of +3.3% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kodiak beats expectations, history suggests a potential stock increase of around 1.34% on average, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may see muted reactions as investors assess the commentary for future guidance.
Miss
A miss could lead to a decline of about 1.34%, as investors may react negatively to continued losses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ARCHER AVIATION INC A
May 11, 2026